Cellares, which last year became the first company to receive the FDA's new advanced manufacturing technology designation, ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, ...

Orphan drug designation is granted by the FDA for therapies treating rare disease affecting fewer than 200,000 patients in the U.S., and provides development incentives including extended market ...

RADNOR, PA & PHILADELPHIA, PA — Avantor, Inc. (NYSE: AVTR) has entered into a strategic partnership with BlueWhale Bio, a commercial-stage biotechnology firm focused on improving immune cell therapy ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and City of Hope ®, one of the largest and most advanced cancer research and treatment organizations in the United ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

Market OverviewThe global cell and gene therapy market is undergoing rapid and transformative growth, reflecting its increasing importance in modern healthcare.The market is projected to expand at a ...